TLPT Oncology for Clinicians: Transversal–Longitudinal Modeling, Master‑Switch Architecture, Pathologic Attractors, and Clinical Applications

Abstract

The Transversal–Longitudinal Pathogenetic Theory (TLPT) provides a mechanistic clinical framework for solid oncology by mapping routine biomarkers to master‑switch activation and pathological attractor formation. Solid tumors such as glioblastoma, melanoma, pancreatic carcinoma, colorectal carcinoma, breast carcinoma, sarcomas, and invasive lung carcinoma exhibit transversal and longitudinal features that cannot be fully explained by descriptive models like TNM staging or WHO classifications. TLPT identifies four fundamental pathological attractors—APIHAP, APIP, APHF, and APIM—each defined by specific constellations of inflammation, hypoxia, angiogenesis, proliferation, fibrosis, mesenchymal remodeling, metabolic dysfunction, and redox vulnerability. These attractors arise from activation or inhibition of master‑switches including NF‑κB, HIF‑1α, mTOR, TGF‑β, PPAR, and Nrf2. The document provides a complete clinical synthesis integrating hematologic, biochemical, inflammatory, metabolic, redox, and histological biomarkers, enabling clinicians to interpret laboratory data mechanistically, anticipate disease trajectory, and apply therapeutic modulation according to the S_blocaj sequence. TLPT Oncology for Clinicians complements conventional oncologic frameworks by offering a unified pathogenetic architecture for diagnostic interpretation and therapeutic decision‑making.